Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
The general manager explains how vision behind the setting up of Grupo Rasch was to represent companies, primarily European and high-tech ones, in the manufacturing of drugs reveals and how…
The future of healthcare calls for all stakeholders to partner up. The general manager for Johnson & Johnson (J&J) Medical in Mexico shares his view about the challenges the healthcare…
The CEO of DefiLatina Healthcare reveals how a reliance on social security has seen the public health system struggle to meet the demands placed upon it, how her company´s vision…
The CEO and president of Smart Scale explains how the company delivers clever and innovate information technology services to the pharmaceutical industry, acting as a significant partner for both information…
Eduardo Tapia explains how big changes in the distribution landscape are transforming the industry, reveals how the life sciences sector has been positioned as a global priority for DHL, and…
Eric Alvarez, managing director of Janssen Mexico, explains why it is important to distinguish between the public and private sector when discussing the latest developments in the pharmaceutical industry, and…
Teleflex is committed to solving the challenges of a changing healthcare environment in the areas of critical care and surgical applications by providing every day new products. The managing director…
Internationalization and innovation are part of Chiesi’s history. The general manager of the recently started Mexican affiliate discusses the company’s priorities for the second largest market in Latin America and…
Cecilia Calderón shares her experience as founder and general manager of Vigpharma, her perspectives on the pharmacovigilance and technovigilance in Mexico and the main challenges that come with being the…
The director of Bacher Zoppi reveals how the Mexican pharma sector is back in the spotlight of the international investor community, explains how the distribution environment has evolved with power…
The corporate development director and business development manager of UpPharma explain why Market Expansion Services (MES) model represents a unique business opportunity for firms looking to establish themselves in the…
The councillor at the Swiss Embassy talks about how the two countries have a particularly close relationship when it comes to pharma, the challenge of introducing innovative products to the…
See our Cookie Privacy Policy Here
